Ningbo David Medical Device Co., Ltd. (SHE:300314)
China · Delayed Price · Currency is CNY 14.25
-0.06 (-0.42%)
Feb 13, 2026, 3:04 PM CST
SHE:300314 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 506.66 | 516.93 | 606.83 | 496.58 | 469.87 | 455.63 |
Other Revenue | 10.1 | 10.1 | 11.47 | 9.46 | 4.26 | 3.9 |
| 516.76 | 527.03 | 618.3 | 506.04 | 474.13 | 459.53 | |
Revenue Growth (YoY) | -8.09% | -14.76% | 22.18% | 6.73% | 3.18% | 28.95% |
Cost of Revenue | 230.43 | 233.47 | 263.61 | 210.28 | 185.25 | 189.66 |
Gross Profit | 286.33 | 293.55 | 354.68 | 295.76 | 288.88 | 269.87 |
Selling, General & Admin | 168.19 | 172.44 | 172.15 | 155.19 | 166.5 | 123.36 |
Research & Development | 57.35 | 55.46 | 48.06 | 45.87 | 49.69 | 40.22 |
Other Operating Expenses | 3.42 | 5.03 | 6.72 | 7.98 | 6.81 | 6.96 |
Operating Expenses | 228.53 | 233.16 | 227.43 | 210.26 | 223.27 | 170.9 |
Operating Income | 57.8 | 60.39 | 127.25 | 85.5 | 65.61 | 98.97 |
Interest Expense | -0.41 | -0.47 | -0.6 | -0.35 | -0.03 | - |
Interest & Investment Income | 24.08 | 10.71 | 25.87 | 5.39 | 18.9 | 49.4 |
Currency Exchange Gain (Loss) | 0.83 | 0.83 | 6.33 | 17.05 | -2.86 | -3.3 |
Other Non Operating Income (Expenses) | -0.89 | -0.46 | -0.3 | -0.27 | -0.23 | -0.26 |
EBT Excluding Unusual Items | 81.41 | 71.01 | 158.55 | 107.31 | 81.38 | 144.81 |
Impairment of Goodwill | -0.52 | -0.52 | -1.53 | - | - | - |
Gain (Loss) on Sale of Investments | -9.19 | -10.06 | 0.26 | -4.88 | 0.69 | - |
Gain (Loss) on Sale of Assets | -0.42 | -0.01 | -0.23 | 0.02 | 0.12 | 0 |
Asset Writedown | -0.01 | -0.01 | -0.08 | -0.02 | -0.04 | -0.03 |
Other Unusual Items | 2.41 | 2.98 | 9.24 | 9.49 | 5.05 | 1.86 |
Pretax Income | 73.69 | 63.38 | 166.22 | 111.92 | 87.19 | 146.65 |
Income Tax Expense | 7.12 | 6.12 | 18.61 | 14.56 | 6.99 | 10.46 |
Net Income | 66.57 | 57.26 | 147.61 | 97.36 | 80.21 | 136.19 |
Net Income to Common | 66.57 | 57.26 | 147.61 | 97.36 | 80.21 | 136.19 |
Net Income Growth | -24.45% | -61.21% | 51.62% | 21.39% | -41.11% | 119.46% |
Shares Outstanding (Basic) | 286 | 286 | 289 | 286 | 286 | 290 |
Shares Outstanding (Diluted) | 286 | 286 | 289 | 286 | 286 | 290 |
Shares Change (YoY) | -1.08% | -1.08% | 1.08% | -0.04% | -1.14% | 2.73% |
EPS (Basic) | 0.23 | 0.20 | 0.51 | 0.34 | 0.28 | 0.47 |
EPS (Diluted) | 0.23 | 0.20 | 0.51 | 0.34 | 0.28 | 0.47 |
EPS Growth | -23.63% | -60.78% | 50.00% | 21.43% | -40.43% | 113.64% |
Free Cash Flow | 15.24 | -45.82 | 94.81 | 61.79 | 44.95 | 113.53 |
Free Cash Flow Per Share | 0.05 | -0.16 | 0.33 | 0.22 | 0.16 | 0.39 |
Dividend Per Share | 0.087 | 0.087 | 0.180 | 0.150 | 0.100 | 0.150 |
Dividend Growth | -51.67% | -51.67% | 20.00% | 50.00% | -33.33% | 275.00% |
Gross Margin | 55.41% | 55.70% | 57.36% | 58.45% | 60.93% | 58.73% |
Operating Margin | 11.19% | 11.46% | 20.58% | 16.89% | 13.84% | 21.54% |
Profit Margin | 12.88% | 10.87% | 23.87% | 19.24% | 16.92% | 29.64% |
Free Cash Flow Margin | 2.95% | -8.70% | 15.33% | 12.21% | 9.48% | 24.70% |
EBITDA | 77.19 | 83.18 | 154.57 | 108.93 | 89.76 | 120.46 |
EBITDA Margin | 14.94% | 15.78% | 25.00% | 21.53% | 18.93% | 26.21% |
D&A For EBITDA | 19.39 | 22.79 | 27.32 | 23.43 | 24.15 | 21.49 |
EBIT | 57.8 | 60.39 | 127.25 | 85.5 | 65.61 | 98.97 |
EBIT Margin | 11.19% | 11.46% | 20.58% | 16.89% | 13.84% | 21.54% |
Effective Tax Rate | 9.66% | 9.65% | 11.20% | 13.01% | 8.01% | 7.13% |
Revenue as Reported | 516.76 | 527.03 | 618.3 | 506.04 | 474.13 | 459.53 |
Advertising Expenses | - | 3.22 | 4.51 | 3.32 | 4.06 | 1.34 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.